Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 7,920 shares of the firm’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $12.27, for a total transaction of $97,178.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Monday, March 18th, Matt Davidson sold 11,626 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $12.26, for a total transaction of $142,534.76.
  • On Wednesday, March 13th, Matt Davidson sold 25,045 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.55, for a total transaction of $289,269.75.
  • On Friday, March 8th, Matt Davidson sold 20,558 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.72, for a total transaction of $240,939.76.
  • On Tuesday, March 5th, Matt Davidson sold 25,830 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $12.46, for a total transaction of $321,841.80.
  • On Thursday, February 28th, Matt Davidson sold 14,305 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.26, for a total transaction of $161,074.30.
  • On Monday, February 25th, Matt Davidson sold 13,071 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.05, for a total transaction of $144,434.55.
  • On Wednesday, February 20th, Matt Davidson sold 13,544 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.33, for a total transaction of $153,453.52.
  • On Thursday, February 14th, Matt Davidson sold 13,191 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.36, for a total transaction of $163,040.76.
  • On Monday, February 11th, Matt Davidson sold 13,057 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $13.53, for a total transaction of $176,661.21.
  • On Wednesday, February 6th, Matt Davidson sold 15,859 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.93, for a total transaction of $205,056.87.

VRCA stock traded up $0.22 during trading on Thursday, reaching $12.29. 27,863 shares of the stock were exchanged, compared to its average volume of 90,956. Verrica Pharmaceuticals Inc has a 1 year low of $6.44 and a 1 year high of $23.29. The company has a market capitalization of $315.98 million and a PE ratio of -8.72.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Thursday, March 7th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). As a group, analysts anticipate that Verrica Pharmaceuticals Inc will post -1.14 earnings per share for the current fiscal year.

A number of brokerages have commented on VRCA. Zacks Investment Research downgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 30th. HC Wainwright began coverage on shares of Verrica Pharmaceuticals in a research note on Thursday, February 21st. They set a “buy” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $26.25.

Hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund purchased a new position in Verrica Pharmaceuticals during the fourth quarter worth about $28,000. Beck Mack & Oliver LLC purchased a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $82,000. Capital Investment Advisory Services LLC raised its stake in shares of Verrica Pharmaceuticals by 15.9% in the 4th quarter. Capital Investment Advisory Services LLC now owns 12,400 shares of the company’s stock valued at $101,000 after acquiring an additional 1,700 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Verrica Pharmaceuticals by 39.1% in the 4th quarter. Bank of New York Mellon Corp now owns 16,662 shares of the company’s stock valued at $136,000 after acquiring an additional 4,681 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Verrica Pharmaceuticals by 31.7% in the 4th quarter. Geode Capital Management LLC now owns 36,906 shares of the company’s stock valued at $300,000 after acquiring an additional 8,885 shares during the period. 32.86% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/03/21/verrica-pharmaceuticals-inc-vrca-major-shareholder-matt-davidson-sells-7920-shares.html.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.